Professor Yong Huo
Peking University First Hospital, Beijing (China)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Event: ESC Congress 2020
Topic: Cardiovascular Pharmacotherapy
Session: Pharmacology and Pharmacotherapy ePosters
Stroke prevention from lifestyle to intervention
Event: ESC Congress 2017
Topic: Treatment of hypertension
Session: Heart and brain interaction
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Event: ESC Asia with APSC & AFC 2020
Topic: Cardiovascular Pharmacotherapy
Session: Abstract Programme
ESC 365 is supported by
